nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—CYP2D6—Bicalutamide—prostate cancer	0.0337	0.504	CbGbCtD
Zuclopenthixol—CYP2D6—Abiraterone—prostate cancer	0.0279	0.418	CbGbCtD
Zuclopenthixol—CYP2D6—Doxorubicin—prostate cancer	0.00516	0.0773	CbGbCtD
Zuclopenthixol—Perphenazine—AOX1—prostate cancer	0.0012	0.107	CrCbGaD
Zuclopenthixol—Domperidone—CYP3A5—prostate cancer	0.000716	0.0644	CrCbGaD
Zuclopenthixol—Thioproperazine—SLC22A1—prostate cancer	0.000649	0.0584	CrCbGaD
Zuclopenthixol—Thiothixene—SLC22A1—prostate cancer	0.000639	0.0574	CrCbGaD
Zuclopenthixol—Pipotiazine—SLC22A1—prostate cancer	0.000639	0.0574	CrCbGaD
Zuclopenthixol—Nefazodone—CYP3A5—prostate cancer	0.000595	0.0535	CrCbGaD
Zuclopenthixol—Trazodone—CYP3A5—prostate cancer	0.00055	0.0495	CrCbGaD
Zuclopenthixol—Perphenazine—CYP2C18—prostate cancer	0.000535	0.0481	CrCbGaD
Zuclopenthixol—Clozapine—CYP1B1—prostate cancer	0.000373	0.0336	CrCbGaD
Zuclopenthixol—Pipotiazine—CYP2C19—prostate cancer	0.000351	0.0316	CrCbGaD
Zuclopenthixol—Chlorpromazine—SLC22A1—prostate cancer	0.000346	0.0311	CrCbGaD
Zuclopenthixol—Quetiapine—CYP3A5—prostate cancer	0.000345	0.0311	CrCbGaD
Zuclopenthixol—Domperidone—CYP3A4—prostate cancer	0.00031	0.0279	CrCbGaD
Zuclopenthixol—Fluphenazine—CYP2E1—prostate cancer	0.000306	0.0275	CrCbGaD
Zuclopenthixol—Clozapine—CYP2A6—prostate cancer	0.000288	0.0259	CrCbGaD
Zuclopenthixol—Thioridazine—CYP2E1—prostate cancer	0.000264	0.0237	CrCbGaD
Zuclopenthixol—Thioridazine—CYP2C19—prostate cancer	0.000261	0.0235	CrCbGaD
Zuclopenthixol—Nefazodone—CYP3A4—prostate cancer	0.000257	0.0231	CrCbGaD
Zuclopenthixol—Perphenazine—CYP2C19—prostate cancer	0.00024	0.0216	CrCbGaD
Zuclopenthixol—Trazodone—CYP3A4—prostate cancer	0.000238	0.0214	CrCbGaD
Zuclopenthixol—Quetiapine—CYP2C19—prostate cancer	0.000235	0.0211	CrCbGaD
Zuclopenthixol—Pipotiazine—CYP3A4—prostate cancer	0.000223	0.0201	CrCbGaD
Zuclopenthixol—HTR2A—urine—prostate cancer	0.000222	0.138	CbGeAlD
Zuclopenthixol—Prochlorperazine—CYP3A4—prostate cancer	0.000213	0.0192	CrCbGaD
Zuclopenthixol—Clozapine—CYP2E1—prostate cancer	0.000204	0.0184	CrCbGaD
Zuclopenthixol—CYP2D6—urine—prostate cancer	0.000202	0.125	CbGeAlD
Zuclopenthixol—Clozapine—CYP2C19—prostate cancer	0.000202	0.0182	CrCbGaD
Zuclopenthixol—Clozapine—CYP1A1—prostate cancer	0.000201	0.0181	CrCbGaD
Zuclopenthixol—Chlorpromazine—CYP2E1—prostate cancer	0.000192	0.0173	CrCbGaD
Zuclopenthixol—Shock—Capecitabine—prostate cancer	0.000177	0.000256	CcSEcCtD
Zuclopenthixol—Abdominal pain—Etoposide—prostate cancer	0.000177	0.000256	CcSEcCtD
Zuclopenthixol—Body temperature increased—Etoposide—prostate cancer	0.000177	0.000256	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Capecitabine—prostate cancer	0.000176	0.000255	CcSEcCtD
Zuclopenthixol—Vertigo—Prednisone—prostate cancer	0.000176	0.000255	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Capecitabine—prostate cancer	0.000176	0.000255	CcSEcCtD
Zuclopenthixol—Syncope—Prednisone—prostate cancer	0.000176	0.000255	CcSEcCtD
Zuclopenthixol—Tachycardia—Capecitabine—prostate cancer	0.000175	0.000254	CcSEcCtD
Zuclopenthixol—Skin disorder—Capecitabine—prostate cancer	0.000175	0.000253	CcSEcCtD
Zuclopenthixol—Sweating—Doxorubicin—prostate cancer	0.000174	0.000252	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Epirubicin—prostate cancer	0.000174	0.000252	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Capecitabine—prostate cancer	0.000174	0.000251	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Epirubicin—prostate cancer	0.000174	0.000251	CcSEcCtD
Zuclopenthixol—Hypotension—Docetaxel—prostate cancer	0.000173	0.000251	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Epirubicin—prostate cancer	0.000173	0.000251	CcSEcCtD
Zuclopenthixol—Urethral disorder—Epirubicin—prostate cancer	0.000173	0.00025	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Prednisone—prostate cancer	0.000172	0.000249	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000172	0.000249	CcSEcCtD
Zuclopenthixol—Anorexia—Capecitabine—prostate cancer	0.000171	0.000248	CcSEcCtD
Zuclopenthixol—Nausea—Estradiol—prostate cancer	0.000171	0.000248	CcSEcCtD
Zuclopenthixol—Vomiting—Mitoxantrone—prostate cancer	0.000171	0.000247	CcSEcCtD
Zuclopenthixol—Convulsion—Prednisone—prostate cancer	0.00017	0.000246	CcSEcCtD
Zuclopenthixol—Visual impairment—Epirubicin—prostate cancer	0.00017	0.000246	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Doxorubicin—prostate cancer	0.00017	0.000245	CcSEcCtD
Zuclopenthixol—Hypertension—Prednisone—prostate cancer	0.000169	0.000245	CcSEcCtD
Zuclopenthixol—Rash—Mitoxantrone—prostate cancer	0.000169	0.000245	CcSEcCtD
Zuclopenthixol—Dermatitis—Mitoxantrone—prostate cancer	0.000169	0.000245	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000169	0.000245	CcSEcCtD
Zuclopenthixol—Headache—Mitoxantrone—prostate cancer	0.000168	0.000243	CcSEcCtD
Zuclopenthixol—Hypotension—Capecitabine—prostate cancer	0.000168	0.000243	CcSEcCtD
Zuclopenthixol—Insomnia—Docetaxel—prostate cancer	0.000168	0.000243	CcSEcCtD
Zuclopenthixol—Myalgia—Prednisone—prostate cancer	0.000167	0.000242	CcSEcCtD
Zuclopenthixol—Paraesthesia—Docetaxel—prostate cancer	0.000167	0.000241	CcSEcCtD
Zuclopenthixol—Anxiety—Prednisone—prostate cancer	0.000166	0.000241	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000166	0.00024	CcSEcCtD
Zuclopenthixol—Dyspnoea—Docetaxel—prostate cancer	0.000166	0.000239	CcSEcCtD
Zuclopenthixol—Somnolence—Docetaxel—prostate cancer	0.000165	0.000239	CcSEcCtD
Zuclopenthixol—Discomfort—Prednisone—prostate cancer	0.000165	0.000239	CcSEcCtD
Zuclopenthixol—Eye disorder—Epirubicin—prostate cancer	0.000165	0.000238	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Etoposide—prostate cancer	0.000165	0.000238	CcSEcCtD
Zuclopenthixol—Tinnitus—Epirubicin—prostate cancer	0.000164	0.000238	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000164	0.000237	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Epirubicin—prostate cancer	0.000164	0.000237	CcSEcCtD
Zuclopenthixol—Dyspepsia—Docetaxel—prostate cancer	0.000163	0.000236	CcSEcCtD
Zuclopenthixol—Insomnia—Capecitabine—prostate cancer	0.000163	0.000235	CcSEcCtD
Zuclopenthixol—Paraesthesia—Capecitabine—prostate cancer	0.000161	0.000234	CcSEcCtD
Zuclopenthixol—Decreased appetite—Docetaxel—prostate cancer	0.000161	0.000233	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Doxorubicin—prostate cancer	0.000161	0.000233	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Doxorubicin—prostate cancer	0.000161	0.000232	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Docetaxel—prostate cancer	0.00016	0.000232	CcSEcCtD
Zuclopenthixol—Asthenia—Etoposide—prostate cancer	0.00016	0.000232	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Doxorubicin—prostate cancer	0.00016	0.000232	CcSEcCtD
Zuclopenthixol—Dyspnoea—Capecitabine—prostate cancer	0.00016	0.000232	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Prednisone—prostate cancer	0.00016	0.000232	CcSEcCtD
Zuclopenthixol—Fatigue—Docetaxel—prostate cancer	0.00016	0.000232	CcSEcCtD
Zuclopenthixol—Angiopathy—Epirubicin—prostate cancer	0.00016	0.000231	CcSEcCtD
Zuclopenthixol—Urethral disorder—Doxorubicin—prostate cancer	0.00016	0.000231	CcSEcCtD
Zuclopenthixol—Nausea—Mitoxantrone—prostate cancer	0.00016	0.000231	CcSEcCtD
Zuclopenthixol—Immune system disorder—Epirubicin—prostate cancer	0.000159	0.00023	CcSEcCtD
Zuclopenthixol—Constipation—Docetaxel—prostate cancer	0.000159	0.00023	CcSEcCtD
Zuclopenthixol—Pain—Docetaxel—prostate cancer	0.000159	0.00023	CcSEcCtD
Zuclopenthixol—Dyspepsia—Capecitabine—prostate cancer	0.000158	0.000229	CcSEcCtD
Zuclopenthixol—Pruritus—Etoposide—prostate cancer	0.000158	0.000229	CcSEcCtD
Zuclopenthixol—Shock—Prednisone—prostate cancer	0.000158	0.000228	CcSEcCtD
Zuclopenthixol—Arrhythmia—Epirubicin—prostate cancer	0.000157	0.000228	CcSEcCtD
Zuclopenthixol—Visual impairment—Doxorubicin—prostate cancer	0.000157	0.000227	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Prednisone—prostate cancer	0.000157	0.000227	CcSEcCtD
Zuclopenthixol—Tachycardia—Prednisone—prostate cancer	0.000156	0.000226	CcSEcCtD
Zuclopenthixol—Decreased appetite—Capecitabine—prostate cancer	0.000156	0.000226	CcSEcCtD
Zuclopenthixol—Skin disorder—Prednisone—prostate cancer	0.000156	0.000225	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000155	0.000225	CcSEcCtD
Zuclopenthixol—Fatigue—Capecitabine—prostate cancer	0.000155	0.000224	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Prednisone—prostate cancer	0.000155	0.000224	CcSEcCtD
Zuclopenthixol—Mental disorder—Epirubicin—prostate cancer	0.000154	0.000223	CcSEcCtD
Zuclopenthixol—Pain—Capecitabine—prostate cancer	0.000154	0.000222	CcSEcCtD
Zuclopenthixol—Constipation—Capecitabine—prostate cancer	0.000154	0.000222	CcSEcCtD
Zuclopenthixol—Erythema—Epirubicin—prostate cancer	0.000153	0.000222	CcSEcCtD
Zuclopenthixol—Malnutrition—Epirubicin—prostate cancer	0.000153	0.000222	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Docetaxel—prostate cancer	0.000153	0.000221	CcSEcCtD
Zuclopenthixol—Diarrhoea—Etoposide—prostate cancer	0.000153	0.000221	CcSEcCtD
Zuclopenthixol—Anorexia—Prednisone—prostate cancer	0.000153	0.000221	CcSEcCtD
Zuclopenthixol—Perphenazine—CYP3A4—prostate cancer	0.000152	0.0137	CrCbGaD
Zuclopenthixol—Eye disorder—Doxorubicin—prostate cancer	0.000152	0.000221	CcSEcCtD
Zuclopenthixol—Tinnitus—Doxorubicin—prostate cancer	0.000152	0.00022	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Docetaxel—prostate cancer	0.000152	0.00022	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Doxorubicin—prostate cancer	0.000151	0.000219	CcSEcCtD
Zuclopenthixol—Flatulence—Epirubicin—prostate cancer	0.000151	0.000219	CcSEcCtD
Zuclopenthixol—Tension—Epirubicin—prostate cancer	0.000151	0.000218	CcSEcCtD
Zuclopenthixol—Quetiapine—CYP3A4—prostate cancer	0.00015	0.0134	CrCbGaD
Zuclopenthixol—Nervousness—Epirubicin—prostate cancer	0.000149	0.000216	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Capecitabine—prostate cancer	0.000148	0.000214	CcSEcCtD
Zuclopenthixol—Angiopathy—Doxorubicin—prostate cancer	0.000148	0.000214	CcSEcCtD
Zuclopenthixol—Dizziness—Etoposide—prostate cancer	0.000148	0.000214	CcSEcCtD
Zuclopenthixol—Immune system disorder—Doxorubicin—prostate cancer	0.000147	0.000213	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Capecitabine—prostate cancer	0.000147	0.000213	CcSEcCtD
Zuclopenthixol—Body temperature increased—Docetaxel—prostate cancer	0.000147	0.000212	CcSEcCtD
Zuclopenthixol—Abdominal pain—Docetaxel—prostate cancer	0.000147	0.000212	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000146	0.000211	CcSEcCtD
Zuclopenthixol—Arrhythmia—Doxorubicin—prostate cancer	0.000146	0.000211	CcSEcCtD
Zuclopenthixol—Insomnia—Prednisone—prostate cancer	0.000145	0.00021	CcSEcCtD
Zuclopenthixol—Vision blurred—Epirubicin—prostate cancer	0.000145	0.000209	CcSEcCtD
Zuclopenthixol—Paraesthesia—Prednisone—prostate cancer	0.000144	0.000208	CcSEcCtD
Zuclopenthixol—Mental disorder—Doxorubicin—prostate cancer	0.000143	0.000207	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Epirubicin—prostate cancer	0.000142	0.000206	CcSEcCtD
Zuclopenthixol—Abdominal pain—Capecitabine—prostate cancer	0.000142	0.000206	CcSEcCtD
Zuclopenthixol—Body temperature increased—Capecitabine—prostate cancer	0.000142	0.000206	CcSEcCtD
Zuclopenthixol—Vomiting—Etoposide—prostate cancer	0.000142	0.000206	CcSEcCtD
Zuclopenthixol—Erythema—Doxorubicin—prostate cancer	0.000142	0.000205	CcSEcCtD
Zuclopenthixol—Malnutrition—Doxorubicin—prostate cancer	0.000142	0.000205	CcSEcCtD
Zuclopenthixol—Agitation—Epirubicin—prostate cancer	0.000141	0.000204	CcSEcCtD
Zuclopenthixol—Dyspepsia—Prednisone—prostate cancer	0.000141	0.000204	CcSEcCtD
Zuclopenthixol—Rash—Etoposide—prostate cancer	0.000141	0.000204	CcSEcCtD
Zuclopenthixol—Dermatitis—Etoposide—prostate cancer	0.000141	0.000204	CcSEcCtD
Zuclopenthixol—Headache—Etoposide—prostate cancer	0.00014	0.000202	CcSEcCtD
Zuclopenthixol—Flatulence—Doxorubicin—prostate cancer	0.00014	0.000202	CcSEcCtD
Zuclopenthixol—Tension—Doxorubicin—prostate cancer	0.000139	0.000202	CcSEcCtD
Zuclopenthixol—Decreased appetite—Prednisone—prostate cancer	0.000139	0.000201	CcSEcCtD
Zuclopenthixol—Malaise—Epirubicin—prostate cancer	0.000138	0.0002	CcSEcCtD
Zuclopenthixol—Fatigue—Prednisone—prostate cancer	0.000138	0.0002	CcSEcCtD
Zuclopenthixol—Nervousness—Doxorubicin—prostate cancer	0.000138	0.000199	CcSEcCtD
Zuclopenthixol—Vertigo—Epirubicin—prostate cancer	0.000138	0.000199	CcSEcCtD
Zuclopenthixol—Syncope—Epirubicin—prostate cancer	0.000138	0.000199	CcSEcCtD
Zuclopenthixol—Leukopenia—Epirubicin—prostate cancer	0.000137	0.000199	CcSEcCtD
Zuclopenthixol—Constipation—Prednisone—prostate cancer	0.000137	0.000198	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Docetaxel—prostate cancer	0.000137	0.000198	CcSEcCtD
Zuclopenthixol—Palpitations—Epirubicin—prostate cancer	0.000136	0.000196	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Epirubicin—prostate cancer	0.000135	0.000195	CcSEcCtD
Zuclopenthixol—Vision blurred—Doxorubicin—prostate cancer	0.000134	0.000194	CcSEcCtD
Zuclopenthixol—Asthenia—Docetaxel—prostate cancer	0.000133	0.000193	CcSEcCtD
Zuclopenthixol—Convulsion—Epirubicin—prostate cancer	0.000133	0.000192	CcSEcCtD
Zuclopenthixol—Nausea—Etoposide—prostate cancer	0.000133	0.000192	CcSEcCtD
Zuclopenthixol—Hypertension—Epirubicin—prostate cancer	0.000132	0.000192	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Capecitabine—prostate cancer	0.000132	0.000192	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Prednisone—prostate cancer	0.000132	0.000191	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Doxorubicin—prostate cancer	0.000132	0.000191	CcSEcCtD
Zuclopenthixol—Pruritus—Docetaxel—prostate cancer	0.000131	0.00019	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Prednisone—prostate cancer	0.000131	0.000189	CcSEcCtD
Zuclopenthixol—Myalgia—Epirubicin—prostate cancer	0.000131	0.000189	CcSEcCtD
Zuclopenthixol—Agitation—Doxorubicin—prostate cancer	0.00013	0.000189	CcSEcCtD
Zuclopenthixol—Anxiety—Epirubicin—prostate cancer	0.00013	0.000188	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.00013	0.000188	CcSEcCtD
Zuclopenthixol—Discomfort—Epirubicin—prostate cancer	0.000129	0.000187	CcSEcCtD
Zuclopenthixol—Asthenia—Capecitabine—prostate cancer	0.000129	0.000187	CcSEcCtD
Zuclopenthixol—Clozapine—CYP3A4—prostate cancer	0.000129	0.0116	CrCbGaD
Zuclopenthixol—Malaise—Doxorubicin—prostate cancer	0.000128	0.000185	CcSEcCtD
Zuclopenthixol—Dry mouth—Epirubicin—prostate cancer	0.000128	0.000185	CcSEcCtD
Zuclopenthixol—Vertigo—Doxorubicin—prostate cancer	0.000128	0.000185	CcSEcCtD
Zuclopenthixol—Syncope—Doxorubicin—prostate cancer	0.000127	0.000184	CcSEcCtD
Zuclopenthixol—Pruritus—Capecitabine—prostate cancer	0.000127	0.000184	CcSEcCtD
Zuclopenthixol—Leukopenia—Doxorubicin—prostate cancer	0.000127	0.000184	CcSEcCtD
Zuclopenthixol—Diarrhoea—Docetaxel—prostate cancer	0.000127	0.000184	CcSEcCtD
Zuclopenthixol—Abdominal pain—Prednisone—prostate cancer	0.000127	0.000183	CcSEcCtD
Zuclopenthixol—Body temperature increased—Prednisone—prostate cancer	0.000127	0.000183	CcSEcCtD
Zuclopenthixol—Palpitations—Doxorubicin—prostate cancer	0.000125	0.000182	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Epirubicin—prostate cancer	0.000125	0.000181	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Doxorubicin—prostate cancer	0.000125	0.000181	CcSEcCtD
Zuclopenthixol—ADRA1A—prostate gland—prostate cancer	0.000123	0.0764	CbGeAlD
Zuclopenthixol—Shock—Epirubicin—prostate cancer	0.000123	0.000178	CcSEcCtD
Zuclopenthixol—Convulsion—Doxorubicin—prostate cancer	0.000123	0.000178	CcSEcCtD
Zuclopenthixol—Diarrhoea—Capecitabine—prostate cancer	0.000123	0.000178	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Epirubicin—prostate cancer	0.000123	0.000178	CcSEcCtD
Zuclopenthixol—Dizziness—Docetaxel—prostate cancer	0.000123	0.000178	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Epirubicin—prostate cancer	0.000123	0.000177	CcSEcCtD
Zuclopenthixol—Hypertension—Doxorubicin—prostate cancer	0.000123	0.000177	CcSEcCtD
Zuclopenthixol—Tachycardia—Epirubicin—prostate cancer	0.000122	0.000177	CcSEcCtD
Zuclopenthixol—Skin disorder—Epirubicin—prostate cancer	0.000122	0.000176	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Epirubicin—prostate cancer	0.000121	0.000175	CcSEcCtD
Zuclopenthixol—Chlorpromazine—CYP3A4—prostate cancer	0.000121	0.0109	CrCbGaD
Zuclopenthixol—Myalgia—Doxorubicin—prostate cancer	0.000121	0.000175	CcSEcCtD
Zuclopenthixol—Anxiety—Doxorubicin—prostate cancer	0.00012	0.000174	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.00012	0.000174	CcSEcCtD
Zuclopenthixol—Discomfort—Doxorubicin—prostate cancer	0.000119	0.000173	CcSEcCtD
Zuclopenthixol—Anorexia—Epirubicin—prostate cancer	0.000119	0.000173	CcSEcCtD
Zuclopenthixol—Dizziness—Capecitabine—prostate cancer	0.000119	0.000172	CcSEcCtD
Zuclopenthixol—Dry mouth—Doxorubicin—prostate cancer	0.000118	0.000171	CcSEcCtD
Zuclopenthixol—Vomiting—Docetaxel—prostate cancer	0.000118	0.000171	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Prednisone—prostate cancer	0.000118	0.000171	CcSEcCtD
Zuclopenthixol—Rash—Docetaxel—prostate cancer	0.000117	0.000169	CcSEcCtD
Zuclopenthixol—Hypotension—Epirubicin—prostate cancer	0.000117	0.000169	CcSEcCtD
Zuclopenthixol—Dermatitis—Docetaxel—prostate cancer	0.000117	0.000169	CcSEcCtD
Zuclopenthixol—Headache—Docetaxel—prostate cancer	0.000116	0.000168	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Doxorubicin—prostate cancer	0.000116	0.000168	CcSEcCtD
Zuclopenthixol—Asthenia—Prednisone—prostate cancer	0.000115	0.000166	CcSEcCtD
Zuclopenthixol—Vomiting—Capecitabine—prostate cancer	0.000114	0.000165	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.000114	0.000165	CcSEcCtD
Zuclopenthixol—Shock—Doxorubicin—prostate cancer	0.000114	0.000165	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Doxorubicin—prostate cancer	0.000114	0.000164	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Doxorubicin—prostate cancer	0.000113	0.000164	CcSEcCtD
Zuclopenthixol—Rash—Capecitabine—prostate cancer	0.000113	0.000164	CcSEcCtD
Zuclopenthixol—Pruritus—Prednisone—prostate cancer	0.000113	0.000164	CcSEcCtD
Zuclopenthixol—Insomnia—Epirubicin—prostate cancer	0.000113	0.000164	CcSEcCtD
Zuclopenthixol—Dermatitis—Capecitabine—prostate cancer	0.000113	0.000164	CcSEcCtD
Zuclopenthixol—Tachycardia—Doxorubicin—prostate cancer	0.000113	0.000164	CcSEcCtD
Zuclopenthixol—Headache—Capecitabine—prostate cancer	0.000113	0.000163	CcSEcCtD
Zuclopenthixol—Skin disorder—Doxorubicin—prostate cancer	0.000113	0.000163	CcSEcCtD
Zuclopenthixol—Paraesthesia—Epirubicin—prostate cancer	0.000112	0.000163	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Doxorubicin—prostate cancer	0.000112	0.000162	CcSEcCtD
Zuclopenthixol—Dyspnoea—Epirubicin—prostate cancer	0.000112	0.000162	CcSEcCtD
Zuclopenthixol—Somnolence—Epirubicin—prostate cancer	0.000111	0.000161	CcSEcCtD
Zuclopenthixol—Anorexia—Doxorubicin—prostate cancer	0.00011	0.00016	CcSEcCtD
Zuclopenthixol—Nausea—Docetaxel—prostate cancer	0.00011	0.00016	CcSEcCtD
Zuclopenthixol—Dyspepsia—Epirubicin—prostate cancer	0.00011	0.000159	CcSEcCtD
Zuclopenthixol—Diarrhoea—Prednisone—prostate cancer	0.00011	0.000158	CcSEcCtD
Zuclopenthixol—Decreased appetite—Epirubicin—prostate cancer	0.000109	0.000157	CcSEcCtD
Zuclopenthixol—Hypotension—Doxorubicin—prostate cancer	0.000108	0.000157	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000108	0.000156	CcSEcCtD
Zuclopenthixol—Fatigue—Epirubicin—prostate cancer	0.000108	0.000156	CcSEcCtD
Zuclopenthixol—Constipation—Epirubicin—prostate cancer	0.000107	0.000155	CcSEcCtD
Zuclopenthixol—Pain—Epirubicin—prostate cancer	0.000107	0.000155	CcSEcCtD
Zuclopenthixol—Nausea—Capecitabine—prostate cancer	0.000107	0.000154	CcSEcCtD
Zuclopenthixol—Dizziness—Prednisone—prostate cancer	0.000106	0.000153	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000106	0.000153	CcSEcCtD
Zuclopenthixol—Insomnia—Doxorubicin—prostate cancer	0.000105	0.000152	CcSEcCtD
Zuclopenthixol—Paraesthesia—Doxorubicin—prostate cancer	0.000104	0.000151	CcSEcCtD
Zuclopenthixol—Dyspnoea—Doxorubicin—prostate cancer	0.000103	0.000149	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Epirubicin—prostate cancer	0.000103	0.000149	CcSEcCtD
Zuclopenthixol—Somnolence—Doxorubicin—prostate cancer	0.000103	0.000149	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Epirubicin—prostate cancer	0.000102	0.000148	CcSEcCtD
Zuclopenthixol—Dyspepsia—Doxorubicin—prostate cancer	0.000102	0.000148	CcSEcCtD
Zuclopenthixol—Vomiting—Prednisone—prostate cancer	0.000102	0.000147	CcSEcCtD
Zuclopenthixol—Rash—Prednisone—prostate cancer	0.000101	0.000146	CcSEcCtD
Zuclopenthixol—Dermatitis—Prednisone—prostate cancer	0.000101	0.000146	CcSEcCtD
Zuclopenthixol—Decreased appetite—Doxorubicin—prostate cancer	0.000101	0.000146	CcSEcCtD
Zuclopenthixol—Headache—Prednisone—prostate cancer	0.0001	0.000145	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.0001	0.000145	CcSEcCtD
Zuclopenthixol—Fatigue—Doxorubicin—prostate cancer	9.99e-05	0.000145	CcSEcCtD
Zuclopenthixol—Constipation—Doxorubicin—prostate cancer	9.91e-05	0.000143	CcSEcCtD
Zuclopenthixol—Pain—Doxorubicin—prostate cancer	9.91e-05	0.000143	CcSEcCtD
Zuclopenthixol—Body temperature increased—Epirubicin—prostate cancer	9.9e-05	0.000143	CcSEcCtD
Zuclopenthixol—Abdominal pain—Epirubicin—prostate cancer	9.9e-05	0.000143	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Doxorubicin—prostate cancer	9.55e-05	0.000138	CcSEcCtD
Zuclopenthixol—HRH1—prostate gland—prostate cancer	9.54e-05	0.0591	CbGeAlD
Zuclopenthixol—Nausea—Prednisone—prostate cancer	9.51e-05	0.000138	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Doxorubicin—prostate cancer	9.47e-05	0.000137	CcSEcCtD
Zuclopenthixol—ADRA2A—prostate gland—prostate cancer	9.38e-05	0.0581	CbGeAlD
Zuclopenthixol—Hypersensitivity—Epirubicin—prostate cancer	9.22e-05	0.000133	CcSEcCtD
Zuclopenthixol—Body temperature increased—Doxorubicin—prostate cancer	9.16e-05	0.000133	CcSEcCtD
Zuclopenthixol—Abdominal pain—Doxorubicin—prostate cancer	9.16e-05	0.000133	CcSEcCtD
Zuclopenthixol—ADRA1A—epithelium—prostate cancer	9.06e-05	0.0561	CbGeAlD
Zuclopenthixol—Asthenia—Epirubicin—prostate cancer	8.98e-05	0.00013	CcSEcCtD
Zuclopenthixol—Pruritus—Epirubicin—prostate cancer	8.86e-05	0.000128	CcSEcCtD
Zuclopenthixol—Diarrhoea—Epirubicin—prostate cancer	8.57e-05	0.000124	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Doxorubicin—prostate cancer	8.54e-05	0.000124	CcSEcCtD
Zuclopenthixol—ADRA1A—renal system—prostate cancer	8.4e-05	0.0521	CbGeAlD
Zuclopenthixol—Asthenia—Doxorubicin—prostate cancer	8.31e-05	0.00012	CcSEcCtD
Zuclopenthixol—Dizziness—Epirubicin—prostate cancer	8.28e-05	0.00012	CcSEcCtD
Zuclopenthixol—Pruritus—Doxorubicin—prostate cancer	8.2e-05	0.000119	CcSEcCtD
Zuclopenthixol—Vomiting—Epirubicin—prostate cancer	7.96e-05	0.000115	CcSEcCtD
Zuclopenthixol—ADRA2A—seminal vesicle—prostate cancer	7.93e-05	0.0491	CbGeAlD
Zuclopenthixol—Diarrhoea—Doxorubicin—prostate cancer	7.93e-05	0.000115	CcSEcCtD
Zuclopenthixol—Rash—Epirubicin—prostate cancer	7.89e-05	0.000114	CcSEcCtD
Zuclopenthixol—Dermatitis—Epirubicin—prostate cancer	7.89e-05	0.000114	CcSEcCtD
Zuclopenthixol—Headache—Epirubicin—prostate cancer	7.84e-05	0.000114	CcSEcCtD
Zuclopenthixol—Dizziness—Doxorubicin—prostate cancer	7.66e-05	0.000111	CcSEcCtD
Zuclopenthixol—Nausea—Epirubicin—prostate cancer	7.44e-05	0.000108	CcSEcCtD
Zuclopenthixol—Vomiting—Doxorubicin—prostate cancer	7.37e-05	0.000107	CcSEcCtD
Zuclopenthixol—Rash—Doxorubicin—prostate cancer	7.3e-05	0.000106	CcSEcCtD
Zuclopenthixol—Dermatitis—Doxorubicin—prostate cancer	7.3e-05	0.000106	CcSEcCtD
Zuclopenthixol—Headache—Doxorubicin—prostate cancer	7.26e-05	0.000105	CcSEcCtD
Zuclopenthixol—HRH1—epithelium—prostate cancer	7.01e-05	0.0434	CbGeAlD
Zuclopenthixol—Nausea—Doxorubicin—prostate cancer	6.88e-05	9.96e-05	CcSEcCtD
Zuclopenthixol—HRH1—urethra—prostate cancer	6.39e-05	0.0396	CbGeAlD
Zuclopenthixol—ADRA2A—urethra—prostate cancer	6.28e-05	0.0389	CbGeAlD
Zuclopenthixol—HTR2A—epithelium—prostate cancer	5.86e-05	0.0363	CbGeAlD
Zuclopenthixol—HTR2A—renal system—prostate cancer	5.43e-05	0.0337	CbGeAlD
Zuclopenthixol—DRD2—testis—prostate cancer	5.32e-05	0.033	CbGeAlD
Zuclopenthixol—CYP2D6—renal system—prostate cancer	4.95e-05	0.0307	CbGeAlD
Zuclopenthixol—HRH1—testis—prostate cancer	4.2e-05	0.026	CbGeAlD
Zuclopenthixol—ADRA2A—testis—prostate cancer	4.13e-05	0.0256	CbGeAlD
Zuclopenthixol—HTR2A—testis—prostate cancer	3.51e-05	0.0218	CbGeAlD
Zuclopenthixol—CYP2D6—testis—prostate cancer	3.2e-05	0.0198	CbGeAlD
Zuclopenthixol—HRH1—lymph node—prostate cancer	3.05e-05	0.0189	CbGeAlD
Zuclopenthixol—ADRA2A—lymph node—prostate cancer	2.99e-05	0.0185	CbGeAlD
Zuclopenthixol—DRD2—Signaling by GPCR—EGFR—prostate cancer	1.18e-05	5.13e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CREBBP—prostate cancer	1.18e-05	5.13e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCND1—prostate cancer	1.17e-05	5.12e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IGF1—prostate cancer	1.16e-05	5.08e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TP53—prostate cancer	1.16e-05	5.08e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CTNNB1—prostate cancer	1.16e-05	5.07e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IGF1—prostate cancer	1.16e-05	5.07e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—EGFR—prostate cancer	1.16e-05	5.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	1.16e-05	5.04e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—APC—prostate cancer	1.16e-05	5.04e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—EGFR—prostate cancer	1.16e-05	5.04e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	1.15e-05	5.03e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.15e-05	5.02e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—NOS3—prostate cancer	1.15e-05	5.01e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAP2K1—prostate cancer	1.14e-05	4.99e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EGF—prostate cancer	1.14e-05	4.99e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IRS1—prostate cancer	1.14e-05	4.99e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ERCC2—prostate cancer	1.14e-05	4.98e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IGF1—prostate cancer	1.14e-05	4.97e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MMP9—prostate cancer	1.14e-05	4.97e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CD—prostate cancer	1.14e-05	4.95e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CDKN1A—prostate cancer	1.14e-05	4.95e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	1.13e-05	4.95e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PTEN—prostate cancer	1.13e-05	4.94e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—PIK3CA—prostate cancer	1.13e-05	4.91e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAP2K1—prostate cancer	1.13e-05	4.91e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SERPINE1—prostate cancer	1.12e-05	4.9e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAP2K1—prostate cancer	1.12e-05	4.9e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CD—prostate cancer	1.12e-05	4.87e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CD—prostate cancer	1.12e-05	4.86e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—KRAS—prostate cancer	1.11e-05	4.85e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	1.11e-05	4.84e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—PIK3CA—prostate cancer	1.11e-05	4.83e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—AKT1—prostate cancer	1.11e-05	4.82e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SERPINE1—prostate cancer	1.11e-05	4.82e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—PIK3CA—prostate cancer	1.11e-05	4.82e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SERPINE1—prostate cancer	1.1e-05	4.81e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	1.1e-05	4.8e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—INS—prostate cancer	1.1e-05	4.77e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	1.09e-05	4.77e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—KRAS—prostate cancer	1.09e-05	4.77e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MYC—prostate cancer	1.09e-05	4.77e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—KRAS—prostate cancer	1.09e-05	4.76e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TGFB1—prostate cancer	1.09e-05	4.76e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—FGF2—prostate cancer	1.09e-05	4.74e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	1.08e-05	4.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	1.08e-05	4.72e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—EP300—prostate cancer	1.08e-05	4.71e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—MTHFR—prostate cancer	1.07e-05	4.68e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NOS3—prostate cancer	1.07e-05	4.68e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	1.07e-05	4.68e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	1.07e-05	4.67e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—FGF2—prostate cancer	1.07e-05	4.67e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—EGFR—prostate cancer	1.07e-05	4.67e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—FGF2—prostate cancer	1.07e-05	4.66e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IL6—prostate cancer	1.07e-05	4.65e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CB—prostate cancer	1.06e-05	4.62e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IGF1—prostate cancer	1.06e-05	4.62e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NOS3—prostate cancer	1.06e-05	4.6e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	1.05e-05	4.6e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NOS3—prostate cancer	1.05e-05	4.59e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPARA—prostate cancer	1.05e-05	4.59e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—SRC—prostate cancer	1.05e-05	4.58e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTGS2—prostate cancer	1.05e-05	4.58e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—FGF2—prostate cancer	1.05e-05	4.57e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—JAK2—prostate cancer	1.04e-05	4.55e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NOS3—prostate cancer	1.03e-05	4.51e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—JAK2—prostate cancer	1.03e-05	4.47e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	1.02e-05	4.46e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—JAK2—prostate cancer	1.02e-05	4.46e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—VEGFA—prostate cancer	1.02e-05	4.46e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—PIK3CA—prostate cancer	1.02e-05	4.46e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MDM2—prostate cancer	1.02e-05	4.44e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	1.02e-05	4.43e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—STAT3—prostate cancer	1.01e-05	4.42e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—KRAS—prostate cancer	1.01e-05	4.41e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	1.01e-05	4.39e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	1.01e-05	4.39e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	1.01e-05	4.38e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—JAK2—prostate cancer	1e-05	4.38e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—ERBB2—prostate cancer	1e-05	4.38e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—PIK3CA—prostate cancer	1e-05	4.37e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MDM2—prostate cancer	1e-05	4.37e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MDM2—prostate cancer	9.99e-06	4.36e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	9.96e-06	4.34e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CB—prostate cancer	9.9e-06	4.32e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CAV1—prostate cancer	9.9e-06	4.32e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ERBB2—prostate cancer	9.87e-06	4.3e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ERBB2—prostate cancer	9.85e-06	4.3e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	9.85e-06	4.29e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—AKT1—prostate cancer	9.83e-06	4.29e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MDM2—prostate cancer	9.81e-06	4.28e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	9.74e-06	4.25e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—FGF2—prostate cancer	9.74e-06	4.25e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CB—prostate cancer	9.72e-06	4.24e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	9.67e-06	4.22e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NOS3—prostate cancer	9.6e-06	4.19e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	9.54e-06	4.16e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CXCL8—prostate cancer	9.52e-06	4.15e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MYC—prostate cancer	9.42e-06	4.11e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TGFB1—prostate cancer	9.4e-06	4.1e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CXCL8—prostate cancer	9.36e-06	4.08e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CXCL8—prostate cancer	9.34e-06	4.07e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—JAK2—prostate cancer	9.33e-06	4.07e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDKN1B—prostate cancer	9.29e-06	4.05e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PIK3CA—prostate cancer	9.29e-06	4.05e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—EGFR—prostate cancer	9.21e-06	4.02e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—AKT1—prostate cancer	9.19e-06	4.01e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	9.17e-06	4e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTEN—prostate cancer	9.16e-06	3.99e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	9.15e-06	3.99e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	9.15e-06	3.99e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDKN1B—prostate cancer	9.13e-06	3.98e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MDM2—prostate cancer	9.11e-06	3.97e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CASP3—prostate cancer	9.11e-06	3.97e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL2—prostate cancer	9.1e-06	3.97e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—IL6—prostate cancer	9.05e-06	3.95e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	9.05e-06	3.94e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—AKT1—prostate cancer	9.03e-06	3.94e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CG—prostate cancer	9.02e-06	3.93e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TP53—prostate cancer	8.99e-06	3.92e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	8.98e-06	3.92e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CASP3—prostate cancer	8.96e-06	3.91e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	8.95e-06	3.9e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL2—prostate cancer	8.95e-06	3.9e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CASP3—prostate cancer	8.94e-06	3.9e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL2—prostate cancer	8.93e-06	3.89e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—IL6—prostate cancer	8.9e-06	3.88e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—IL6—prostate cancer	8.89e-06	3.87e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCND1—prostate cancer	8.87e-06	3.87e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	8.87e-06	3.86e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	8.86e-06	3.86e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CTNNB1—prostate cancer	8.78e-06	3.83e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CASP3—prostate cancer	8.78e-06	3.83e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL2—prostate cancer	8.76e-06	3.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—EP300—prostate cancer	8.74e-06	3.81e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCND1—prostate cancer	8.72e-06	3.8e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—IL6—prostate cancer	8.72e-06	3.8e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCND1—prostate cancer	8.71e-06	3.8e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—KRAS—prostate cancer	8.7e-06	3.79e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	8.64e-06	3.77e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CTNNB1—prostate cancer	8.62e-06	3.76e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MMP9—prostate cancer	8.61e-06	3.75e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDKN1A—prostate cancer	8.58e-06	3.74e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PTEN—prostate cancer	8.56e-06	3.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCND1—prostate cancer	8.54e-06	3.72e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—INS—prostate cancer	8.54e-06	3.72e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	8.52e-06	3.71e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MMP9—prostate cancer	8.47e-06	3.69e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	8.46e-06	3.69e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MMP9—prostate cancer	8.45e-06	3.68e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	8.44e-06	3.68e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDKN1A—prostate cancer	8.42e-06	3.67e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PTEN—prostate cancer	8.42e-06	3.67e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PTEN—prostate cancer	8.4e-06	3.66e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CREBBP—prostate cancer	8.36e-06	3.64e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—AKT1—prostate cancer	8.35e-06	3.64e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	8.32e-06	3.63e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MMP9—prostate cancer	8.29e-06	3.62e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	8.26e-06	3.6e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PTEN—prostate cancer	8.25e-06	3.59e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	8.23e-06	3.59e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IL6—prostate cancer	8.23e-06	3.59e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—AKT1—prostate cancer	8.22e-06	3.58e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—AKT1—prostate cancer	8.2e-06	3.57e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—EP300—prostate cancer	8.16e-06	3.56e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CASP3—prostate cancer	8.15e-06	3.55e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL2—prostate cancer	8.14e-06	3.55e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—IL6—prostate cancer	8.1e-06	3.53e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	8.04e-06	3.51e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—EP300—prostate cancer	8.03e-06	3.5e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—EP300—prostate cancer	8.01e-06	3.49e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PIK3CA—prostate cancer	8e-06	3.49e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCND1—prostate cancer	7.94e-06	3.46e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SRC—prostate cancer	7.94e-06	3.46e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CD—prostate cancer	7.93e-06	3.46e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—EP300—prostate cancer	7.86e-06	3.43e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	7.86e-06	3.43e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SRC—prostate cancer	7.81e-06	3.4e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SRC—prostate cancer	7.79e-06	3.4e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TP53—prostate cancer	7.74e-06	3.37e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—VEGFA—prostate cancer	7.73e-06	3.37e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MMP9—prostate cancer	7.71e-06	3.36e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	7.68e-06	3.35e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PTEN—prostate cancer	7.66e-06	3.34e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—STAT3—prostate cancer	7.65e-06	3.34e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SRC—prostate cancer	7.65e-06	3.33e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—VEGFA—prostate cancer	7.61e-06	3.32e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—VEGFA—prostate cancer	7.59e-06	3.31e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—AKT1—prostate cancer	7.59e-06	3.31e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—STAT3—prostate cancer	7.53e-06	3.28e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—STAT3—prostate cancer	7.51e-06	3.28e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—NOS3—prostate cancer	7.48e-06	3.26e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	7.47e-06	3.26e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	7.45e-06	3.25e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—STAT3—prostate cancer	7.37e-06	3.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EP300—prostate cancer	7.31e-06	3.19e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MYC—prostate cancer	7.11e-06	3.1e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SRC—prostate cancer	7.1e-06	3.1e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TGFB1—prostate cancer	7.09e-06	3.09e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL6—prostate cancer	7.08e-06	3.09e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MYC—prostate cancer	7e-06	3.05e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MYC—prostate cancer	6.98e-06	3.04e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TGFB1—prostate cancer	6.98e-06	3.04e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TGFB1—prostate cancer	6.97e-06	3.04e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—EGFR—prostate cancer	6.96e-06	3.03e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	6.92e-06	3.02e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CB—prostate cancer	6.91e-06	3.01e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MYC—prostate cancer	6.85e-06	2.99e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—STAT3—prostate cancer	6.85e-06	2.99e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTGS2—prostate cancer	6.85e-06	2.98e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—EGFR—prostate cancer	6.84e-06	2.98e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	6.84e-06	2.98e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—EGFR—prostate cancer	6.83e-06	2.98e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—EGFR—prostate cancer	6.7e-06	2.92e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—KRAS—prostate cancer	6.57e-06	2.86e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKT1—prostate cancer	6.53e-06	2.85e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—KRAS—prostate cancer	6.47e-06	2.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CA—prostate cancer	6.46e-06	2.82e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—KRAS—prostate cancer	6.45e-06	2.81e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MYC—prostate cancer	6.37e-06	2.78e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	6.35e-06	2.77e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KRAS—prostate cancer	6.33e-06	2.76e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EGFR—prostate cancer	6.23e-06	2.71e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CA—prostate cancer	6.04e-06	2.63e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTEN—prostate cancer	5.97e-06	2.6e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	5.94e-06	2.59e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CA—prostate cancer	5.93e-06	2.58e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KRAS—prostate cancer	5.88e-06	2.56e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TP53—prostate cancer	5.84e-06	2.55e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	5.82e-06	2.54e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TP53—prostate cancer	5.75e-06	2.51e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TP53—prostate cancer	5.73e-06	2.5e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—EP300—prostate cancer	5.69e-06	2.48e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TP53—prostate cancer	5.63e-06	2.45e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	5.4e-06	2.36e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL6—prostate cancer	5.35e-06	2.33e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AKT1—prostate cancer	5.28e-06	2.3e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL6—prostate cancer	5.26e-06	2.29e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL6—prostate cancer	5.25e-06	2.29e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TP53—prostate cancer	5.23e-06	2.28e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6—prostate cancer	5.15e-06	2.25e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKT1—prostate cancer	4.93e-06	2.15e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKT1—prostate cancer	4.85e-06	2.12e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKT1—prostate cancer	4.84e-06	2.11e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6—prostate cancer	4.79e-06	2.09e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT1—prostate cancer	4.75e-06	2.07e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT1—prostate cancer	4.42e-06	1.92e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CA—prostate cancer	4.21e-06	1.84e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AKT1—prostate cancer	3.44e-06	1.5e-05	CbGpPWpGaD
